INTERPACE BIOSCIENCES, INC. (IDXG) Gross margin 2016–2025
INTERPACE BIOSCIENCES, INC. (IDXG) gross margin by fiscal year — reported gross profit divided by reported revenue.
62.3%FY2025 · since FY2016: 49.2% → 62.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 62.3% | -1.5 pp |
| FY2024 | 63.8% | +1.2 pp |
| FY2023 | 62.6% | +5.3 pp |
| FY2022 | 57.3% | +0.5 pp |
| FY2021 | 56.8% | +23.7 pp |
| FY2020 | 33.1% | -1.3 pp |
| FY2019 | 34.4% | -19.0 pp |
| FY2018 | 53.4% | -0.3 pp |
| FY2017 | 53.7% | +4.5 pp |
| FY2016 | 49.2% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More IDXG financial trends
IDXG RevenueIDXG Net incomeIDXG Net marginIDXG Gross profitIDXG Operating incomeIDXG Operating marginIDXG Operating cash flowIDXG Free cash flowIDXG Capital expendituresIDXG Return on equityIDXG Stock buybacksIDXG Dividends paidIDXG Total assetsIDXG Total liabilitiesIDXG Shareholders’ equityIDXG overview →